U.S., Sept. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07163624) titled 'UBT251 Injection Phase II (Type 2 Diabetes Mellitus) Study' on Sept. 01.
Brief Summary: The purpose of this study is to evaluate the efficacy of UBT251 injection after 24 weeks of continuous administration in patients with type 2 diabetes mellitus and to recommend the dosing regimen for the Phase III clinical trial.
Study Start Date: March 22
Study Type: INTERVENTIONAL
Condition:
Type 2 Diabetes Mellitus (T2DM)
Intervention:
DRUG: UBT251 Injection 2.0 mg and UBT251 Injection Placebo
UBT251 Injection and UBT251 Injection Placebo once weekly
DRUG: UBT251 Injection 4.0 mg (ID 0.5 mg) and UBT251 Injection Placebo
UBT251 Inject...